CS260090B1 - Method of methoxyphenoxy acetic acids' new amides and hydrazides preparation - Google Patents
Method of methoxyphenoxy acetic acids' new amides and hydrazides preparation Download PDFInfo
- Publication number
- CS260090B1 CS260090B1 CS873398A CS339887A CS260090B1 CS 260090 B1 CS260090 B1 CS 260090B1 CS 873398 A CS873398 A CS 873398A CS 339887 A CS339887 A CS 339887A CS 260090 B1 CS260090 B1 CS 260090B1
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- formula
- och
- hydrazides
- preparation
- reaction
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 7
- 238000002360 preparation method Methods 0.000 title claims description 5
- GDVIZLVBBHYJMF-UHFFFAOYSA-N 2-methoxy-2-phenoxyacetic acid Chemical class COC(C(O)=O)OC1=CC=CC=C1 GDVIZLVBBHYJMF-UHFFFAOYSA-N 0.000 title claims description 4
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 title claims description 4
- 150000001408 amides Chemical class 0.000 title claims description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 12
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 7
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 6
- 238000009835 boiling Methods 0.000 claims description 6
- -1 isopropylamino Chemical group 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 239000007858 starting material Substances 0.000 claims description 3
- JVXJGLIGBHCEDP-UHFFFAOYSA-N 2-(4-methoxyphenoxy)acetyl chloride Chemical compound COC1=CC=C(OCC(Cl)=O)C=C1 JVXJGLIGBHCEDP-UHFFFAOYSA-N 0.000 claims description 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 150000004702 methyl esters Chemical class 0.000 claims 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 6
- 239000000155 melt Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- WVFIRUQCZJLWQX-UHFFFAOYSA-N methyl 2-(3,4,5-trimethoxyphenoxy)acetate Chemical compound COC(=O)COC1=CC(OC)=C(OC)C(OC)=C1 WVFIRUQCZJLWQX-UHFFFAOYSA-N 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- JUFJLZLBSLQYQT-UHFFFAOYSA-N 2-(4-methoxyphenoxy)-n-(2-phenylethyl)acetamide Chemical compound C1=CC(OC)=CC=C1OCC(=O)NCCC1=CC=CC=C1 JUFJLZLBSLQYQT-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- MKQLBNJQQZRQJU-UHFFFAOYSA-N morpholin-4-amine Chemical compound NN1CCOCC1 MKQLBNJQQZRQJU-UHFFFAOYSA-N 0.000 description 2
- LWMPFIOTEAXAGV-UHFFFAOYSA-N piperidin-1-amine Chemical compound NN1CCCCC1 LWMPFIOTEAXAGV-UHFFFAOYSA-N 0.000 description 2
- KJAQRHMKLVGSCG-UHFFFAOYSA-N propan-2-ylhydrazine Chemical compound CC(C)NN KJAQRHMKLVGSCG-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 206010015995 Eyelid ptosis Diseases 0.000 description 1
- 241001464384 Hymenolepis nana Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000000891 anti-reserpine Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- SKHIBNDAFWIOPB-UHFFFAOYSA-N hydron;2-phenylethanamine;chloride Chemical compound Cl.NCCC1=CC=CC=C1 SKHIBNDAFWIOPB-UHFFFAOYSA-N 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- HJMHFWWJFHHQHX-UHFFFAOYSA-N n-(2-phenylethyl)-2-(3,4,5-trimethoxyphenoxy)acetamide Chemical compound COC1=C(OC)C(OC)=CC(OCC(=O)NCCC=2C=CC=CC=2)=C1 HJMHFWWJFHHQHX-UHFFFAOYSA-N 0.000 description 1
- WORCRIQDGRMEIT-UHFFFAOYSA-N n-morpholin-4-yl-2-(3,4,5-trimethoxyphenoxy)acetamide Chemical compound COC1=C(OC)C(OC)=CC(OCC(=O)NN2CCOCC2)=C1 WORCRIQDGRMEIT-UHFFFAOYSA-N 0.000 description 1
- FKPJZKGKPHSKCU-UHFFFAOYSA-N n-piperidin-1-yl-2-(3,4,5-trimethoxyphenoxy)acetamide Chemical compound COC1=C(OC)C(OC)=CC(OCC(=O)NN2CCCCC2)=C1 FKPJZKGKPHSKCU-UHFFFAOYSA-N 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 201000003004 ptosis Diseases 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 231100000925 very toxic Toxicity 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Landscapes
- Hydrogenated Pyridines (AREA)
Description
Vynález se týká způsobu přípravy nových amidů a hydrazidů methoxyfenoxyoctových kyBelin obecného vzorce IThe invention relates to a process for the preparation of novel amides and hydrazides of methoxyphenoxyacetic acids of general formula (I)
RR
CH3OCH 3 O
OCHjCONHR1 (I),OCHjCONHR 1 (I),
R ve kterém R značí atom vodíku nebo methoxyl a R2 je 2-fenylethyl-, isopropylamino-, piperidino- nebo morfolinoskupina.R wherein R is hydrogen or methoxy and R 2 is 2-phenylethyl, isopropylamino, piperidino or morpholino.
Látky obecného vzorce I podle vynálezu jsou meziprodukty syntézy farmakodynamicky účinných sloučenin, použitelných v praxi jako léčiva. Některé z nich samy o sobě vykazují biologické efekty. Tak např. N-(2-fenylethyl)-4-methoxyfenoxyacetamid, který je velmi málo toxický (akutní toxicita u myší při orálním podání LDjq je vyšší než 2 500 mg/kg). V orálních dávkách vyšších než 300 mg/kg tlumí látka spontánní motilltu myší, tj. působí centrálně tlumivě. V orálních dávkách 100 až 300 mg/kg inhibuje signifikantně ptosu u myší, vyvolávanou reserpinem. Má tedy antireserpinový účinek, který je indikátorem antidepresivního účinku u pacientů. V koncentraci 50 /íg/ml působí inhibičně vůči růstu Mycobacteria tuberculosis v testu in vitro. Má dále zřetelně naznačený anthelmintický efekt vůči tasemnici Hymenolepis nana. Další látka podle vynálezu, tj. 1-(3,4,5-trimethoxyfenoxyacetyl)-2-(2-propyl)hydrazin, je rovněž málo toxická u myší; LD^Q = 500 mg/kg i.v. V intravenosní dávce 100 mg/kg vyvolává u anestezovaných normotenzních krys hluboké poklesy krevního tlaku, takže se projevuje jako hypotenzivum.The compounds of formula (I) according to the invention are intermediates for the synthesis of pharmacodynamically active compounds useful in practice as pharmaceuticals. Some of them have biological effects on their own. For example, N- (2-phenylethyl) -4-methoxyphenoxyacetamide, which is very toxic (acute toxicity in mice by oral administration of LDjq is greater than 2,500 mg / kg). At oral doses higher than 300 mg / kg, the substance suppresses spontaneous motility in mice, i.e. acts centrally depressing. At oral doses of 100-300 mg / kg, it significantly inhibits reserpine-induced ptosis in mice. Thus, it has an antireserpine effect, which is an indicator of the antidepressant effect in patients. At a concentration of 50 µg / ml, it inhibits the growth of Mycobacteria tuberculosis in an in vitro assay. It also has a clearly indicated anthelmintic effect on the tapeworm Hymenolepis nana. Another compound of the invention, i.e. 1- (3,4,5-trimethoxyphenoxyacetyl) -2- (2-propyl) hydrazine, is also of low toxicity in mice; LD ≥ Q = 500 mg / kg iv At an intravenous dose of 100 mg / kg, it causes profound blood pressure decreases in anesthetized normotensive rats, thus manifesting itself as a hypotensive agent.
Způsob přípravy látek obecného vzorce X podle vynálezu spočívá v reakcích derivátů methoxyfenoxyoctových kyselin obecného vzorce IIThe process for the preparation of the compounds of the formula (X) according to the invention consists of reactions of methoxyphenoxyacetic acid derivatives of the formula (II)
RR
CH3OOCH2COR2 (II),CH 3 OOCH 2 COR 2 (II),
R ve kterém R značí totéž jako ve vzorci I a R je atom chloru nebo methoxyl, s primárními aminosloučeninami vzorce IIIWherein R is the same as in Formula I and R is chlorine or methoxy, with primary amino compounds of Formula III
H2N-R2 (III), ve kterém R2 značí totéž jako ve vzorci I. Tyto reakce lze provést za různých podmínek.H 2 NR 2 (III), wherein R 2 is the same as in Formula I. These reactions can be performed under various conditions.
V případě použití 4-methoxyfenoxyaoetylohloridu (II, R = H R = Cl) (Fridman S. G., Z. Obšč. Chim. 24, 642, 1954) jako výchozí látky, lze jeho reakce s látkami obecného vzorce III, použitými ve 100% přebytku, provést ve vroucím chloroformu. Používané látky obecného vzorce III jsou vesměs známé a jde o tyto sloučeniny: 2-fenylethylamin (komerčně přístupný), isopropy lhydrazin (Kost A. N., Sagitullin R. S., Z. Obšč. Chim. 33, 867, 1963), 1-aminopiperidin (Zimmer H. et al., J. Am. Chem. Soc. 77, 790, 1955) a 4-aminomorfolin (Zimmer H. et al., předešlá citace). V případě použití methylesteru kyseliny 3,4,5-trimethoxyfenoxyoctové (Protiva M. et al., Collect. Czech. Chem. Commun. 42, 3628, 1977) je nutné reakci s látkami obecného vzorce III provádět za zvýšené teploty: nejméně při teplotě varu ethanolu) výhodněji ve výše vroucích rozpouštědlech (např. vroucí směs toluenu a butanolu), nebo bez prostředí zahříváním komponent na 100 až 150 °C. Látky podle vynálezu jsou vesměs krystalické, takže je lze čistit krystalizaci. Hydrazidy jsou monobazické sloučeniny a poskytují krystaslioké soli, v prvé řadě hydrochloridy. Všechny látky ve vynálezu popsané jsou nové. Jejich identita byla zajištěna jednak analýzami, jednak obvyklými spektrálními metodami.When 4-methoxyphenoxyaoethyl chloride (II, R = HR = Cl) is used (Fridman SG, Z. Obsc. Chim. 24, 642, 1954) as the starting material, its reaction with the compounds of formula III used in 100% excess, in boiling chloroform. The compounds of the general formula III used are generally known and are the following: 2-phenylethylamine (commercially available), isopropy lhydrazine (Kost AN, Sagitullin RS, Z. Ob. Chim. 33, 867, 1963), 1-aminopiperidine (Zimmer H) et al., J. Am. Chem. Soc., 77, 790 (1955) and 4-aminomorpholine (Zimmer H. et al., supra). If 3,4,5-trimethoxyphenoxyacetic acid methyl ester (Protiva M. et al., Collect. Czech. Chem. Commun. 42, 3628, 1977) is used, the reaction with the compounds of the formula III must be carried out at elevated temperature: at least boiling ethanol) more preferably in the above boiling solvents (e.g. boiling mixture of toluene and butanol), or without environment by heating the components to 100-150 ° C. The compounds of the invention are generally crystalline, so that they can be purified by crystallization. Hydrazides are monobasic compounds and provide crystalline salts, primarily hydrochlorides. All substances described in the invention are novel. Their identity was ensured both by analyzes and by usual spectral methods.
Další podrobnosti provedení přípravy látek podle vynálezu jsou uvedeny v příkladech, jejichž účelem je ilustrovat možnosti vynálezu, avšak v žádném případě není jejich účelem všechny tyto možnosti vyčerpávajícím způsobem popisovat.Further details of the preparation of the compounds according to the invention are given in the examples, which are intended to illustrate the possibilities of the invention, but are not intended to be exhaustive.
Přiklad lExample l
N-(2-fenylethyl)-4-methoxyfenoxyacetamidN- (2-phenylethyl) -4-methoxyphenoxyacetamide
K míchanému roztoku 4,84 g 2-fenylethylaminu ve 20 ml chloroformu se přikape roztok 4,2 g 4-methoxyfenoxyacetylchloridu v 10 ml chloroformu. Reakce je exotermní a směs se přivede do varu pod zpětným chladičem bez vnějšího zahřívání. Směs se míchá 4 h, ponechá přes noc v klidu při teplotě místnosti, druhý den se odsaje vyloučený hydrochlorid 2-fenylethylaminu (3,1 g) a promyje se chloroformem. Filtrát se promyje vodou, vysuší a odpaří. Zbytek stáním krystaluje a je to žádaný produkt ve výtěžku 5,7 g (100 %), který po krystalizaci ze směsi toluenu a petroletheru taje při 80 až 81,5 °C.To a stirred solution of 4.84 g of 2-phenylethylamine in 20 ml of chloroform was added dropwise a solution of 4.2 g of 4-methoxyphenoxyacetyl chloride in 10 ml of chloroform. The reaction is exothermic and the mixture is brought to reflux without external heating. The mixture was stirred for 4 h, allowed to stand at room temperature overnight, the precipitated 2-phenylethylamine hydrochloride (3.1 g) was filtered off with suction the next day and washed with chloroform. The filtrate was washed with water, dried and evaporated. The residue crystallizes on standing and is the desired product in a yield of 5.7 g (100%) which, after crystallization from toluene / petroleum ether, melts at 80-81.5 ° C.
Příklad 2Example 2
N-(2-fenylethyl)-3,4,5-trimethoxyfenoxyacetamidN- (2-phenylethyl) -3,4,5-trimethoxyphenoxyacetamide
Směs 5,12 g methylesteru kyseliny 3,4,5-trimethoxyfenoxyoctové, 3,02 g 2-fenylethylaminu a 15 ml ethanolu se vaří 10 h pod zpětným chladičem a odpaří se za sníženého tlaku. Pevný zbytek (6,9 g, 100 %) se krystaluje z vodného methanolu. Čistý produkt taje poprvé při 90 až 92 °C, při dalším zahřívání ztuhne a definitivně taje při 98 °C.A mixture of 5.12 g of 3,4,5-trimethoxyphenoxyacetic acid methyl ester, 3.02 g of 2-phenylethylamine and 15 ml of ethanol is refluxed for 10 h and evaporated under reduced pressure. The solid residue (6.9 g, 100%) was crystallized from aqueous methanol. The pure product melts for the first time at 90-92 ° C, solidifies with further heating and finally melts at 98 ° C.
Příklad 3Example 3
1-(3,4,5-trimethoxyfenoxyacetyl)-2-(2-propyl)hydrazin1- (3,4,5-trimethoxyphenoxyacetyl) -2- (2-propyl) hydrazine
Směs 7,7 g methylesteru kyseliny 3,4,5-trimethoxyfenoxyoctové, 4,5 g isopropylhydrazinu a 0,05 g methoxidu sodného se míchá a zahřívá 12 h pod zpětným chladičem na 100 až 120 °C.A mixture of 7.7 g of 3,4,5-trimethoxyphenoxyacetic acid methyl ester, 4.5 g of isopropylhydrazine and 0.05 g of sodium methoxide is stirred and refluxed at 100 to 120 ° C for 12 h.
Po částečném ochladnutí se tavenina rozpustí ve 250 ml benzenu, roztok se promyje vodou a zásaditý produkt se extrahuje do 75 ml 2,5M-HC1. Oddělený vodný roztok se zalkalizuje 20 ml konc. vodného amoniaku a produkt se extrahuje benzenem. Zpracováním extraktu se získá 7,9 g (88 %) žádané látky, která krystaluje ze směsi cyklohexanu a benzenu a v čistém stavu taje při 80 až 81,5 °C. Působením etherického roztoku chlorovodíku ve 2-propanolu poskytuje hydrochlorid tající při 180,5 až 182,5 °C.After partial cooling, the melt is dissolved in 250 ml of benzene, the solution is washed with water and the basic product is extracted into 75 ml of 2.5M-HCl. The separated aqueous solution was basified with 20 ml conc. aqueous ammonia and the product was extracted with benzene. Workup of the extract yielded 7.9 g (88%) of the desired material which crystallized from a mixture of cyclohexane and benzene and melted pure at 80-81.5 ° C. Treatment with an ethereal solution of hydrogen chloride in 2-propanol gives the hydrochloride melting at 180.5-182.5 ° C.
PřikládáHe attaches
1-(3,4,5-trimethoxyfenoxyacetamido)piperidin1- (3,4,5-trimethoxyphenoxyacetamido) piperidine
Směs 8,3 g methylesteru kyseliny 3,4,5-trimethoxyfenoxyoctové, 3,5 g 1-aminopiperidinu, ml toluenu, 25 ml butanolu a 0,05 g methoxidu sodného se míchá a vaří 4 h pod zpětným chladičem. Část rozpouštědel (15 ml) se oddestiluje a zbytek se ponechá přes noc v chladu. Vyloučený krystalický produkt se filtruje apřekrystalízuje z 18 ml methanolu. Žádaná látka se získá ve výtěžku 3,0 g (29 %); po další krystalizaci z methanolu je zcela čistá a taje při 156,5 až 158 °C.A mixture of 8.3 g of 3,4,5-trimethoxyphenoxyacetic acid methyl ester, 3.5 g of 1-aminopiperidine, ml of toluene, 25 ml of butanol and 0.05 g of sodium methoxide is stirred and refluxed for 4 hours. A portion of the solvents (15 mL) was distilled off and the residue was left overnight. The precipitated crystalline product is filtered and recrystallized from 18 ml of methanol. The title compound was obtained in a yield of 3.0 g (29%); after further crystallization from methanol, it is completely pure and melts at 156.5-158 ° C.
Příklad 5Example 5
4-(3,4,5-trimethoxyfenoxyacetamido)morfolin4- (3,4,5-trimethoxyphenoxyacetamido) morpholine
Směs 7,7 g methylesteru kyseliny 3,4,5-trimethoxyfenoxyoctové, 4,6 g 4-aminomorfolinu a 0,05 g methoxidu sodného se míchá a zahřívá pod zpětným chladičem 3 h na 120 až 125 °C.A mixture of 7.7 g of 3,4,5-trimethoxyphenoxyacetic acid methyl ester, 4.6 g of 4-aminomorpholine and 0.05 g of sodium methoxide is stirred and refluxed at 120 to 125 ° C for 3 h.
Po ochlazení se tavenina rozpustí v 200 ml chloroformu, roztok se promyje vodou, vysuší a odpaří. Získá se 5,4 g (55 %) krystalického produktu, který se rekrystalizuje z benzenu, t.t. 144,5 až 146,5 °C.After cooling, the melt is dissolved in 200 ml of chloroform, the solution is washed with water, dried and evaporated. 5.4 g (55%) of crystalline product are obtained, which is recrystallized from benzene, m.p. 144.5-146.5 ° C.
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CS873398A CS260090B1 (en) | 1987-05-12 | 1987-05-12 | Method of methoxyphenoxy acetic acids' new amides and hydrazides preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CS873398A CS260090B1 (en) | 1987-05-12 | 1987-05-12 | Method of methoxyphenoxy acetic acids' new amides and hydrazides preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CS339887A1 CS339887A1 (en) | 1988-03-15 |
| CS260090B1 true CS260090B1 (en) | 1988-11-15 |
Family
ID=5373916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CS873398A CS260090B1 (en) | 1987-05-12 | 1987-05-12 | Method of methoxyphenoxy acetic acids' new amides and hydrazides preparation |
Country Status (1)
| Country | Link |
|---|---|
| CS (1) | CS260090B1 (en) |
-
1987
- 1987-05-12 CS CS873398A patent/CS260090B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CS339887A1 (en) | 1988-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4430343A (en) | Benzimidazole derivatives, process for the preparation thereof and pharmaceutical composition containing the same | |
| EP0039051A2 (en) | Mannich-base hydroxamic acid prodrugs for the improved bioavailability of non-steroidal anti-inflammatory agents, a process for preparing and a pharmaceutical composition containing them | |
| EP0984934B1 (en) | Novel orally active iron (iii) chelators | |
| US4234584A (en) | Substituted phenylpiperazine derivatives | |
| EP0097821B1 (en) | Dihydropyridines with an antagonistic activity to calcium, process for their preparation, and pharmaceutical compositions containing them | |
| US5852019A (en) | Pyrimidinylpyrazole derivatives | |
| US4073911A (en) | Indolylalkylpiperidines | |
| US4166117A (en) | 1-(Aralkyl)-4-(4-oxo[3H]quinazolin-3-yl)piperidines | |
| HU193333B (en) | Process for production of 2-amino-axazilons and medical preparatives containing thereof | |
| US4221793A (en) | N,N'-Disubstituted piperazine derivative | |
| CA1273335A (en) | Pyrrolo¬1,2-a| ¬4,1|benzoxazepine derivatives | |
| US4500527A (en) | Antihypertensive 4[(3-alkylamino-2-hydroxypropyl)-oxyiminomethyl phenyl]-1,4-dihydropyridines | |
| US4242347A (en) | Hypotensive indolylalkylpiperidyl guanidines and isoureas | |
| FR2618436A1 (en) | PIPERIDINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | |
| CS260090B1 (en) | Method of methoxyphenoxy acetic acids' new amides and hydrazides preparation | |
| US4147786A (en) | 1-Indolylalkyl-3-or 4-trimethyleneurido-piperidines | |
| CS236097B1 (en) | Acylderivatives of 2-piperazinochinazoline and method of their preparation | |
| CS229692B2 (en) | Manufacturing process of derivate 4-phenylquinazoline | |
| FI85139B (en) | FOERFARANDE FOER FRAMSTAELLNING AV NYA TERAPEUTISKT ANVAENDBARA INDOLKARBOXAMIDDERIVAT SAMT DERAS SALTER. | |
| US4530843A (en) | Isoindole amidoxime derivatives | |
| HU192589B (en) | Process for producing 2-/n-pyrrolidino/-3-isobuthyloxy-n-/substituted phenyl/-n-benzyl-propyl-amines and acid additional salts thereof | |
| EP0078546B1 (en) | Novel imidazolecarboxamide derivatives | |
| US4843085A (en) | Pyridine derivatives, process for production thereof and pharmaceutical compositions useful as anti-arhytmics | |
| NO881899L (en) | NEW 2-AMINOALKYL-4-BENZYL-1- (2H) -PHTHALAZINO DERIVATIVES. | |
| CZ357190A3 (en) | Dihydropyrimidothiazine derivatives, process of their preparation and pharmaceutical compositions containing thereof |